NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Drug Manufacturers - Specialty & Generic · USD

ADC Therapeutics SA (ADCT) Stock Analysis

ADC Therapeutics SA (ADCT) is a Drug Manufacturers - Specialty & Generic stock listed on NYSE and quoted in US Dollar.

ADCT

$1.36

+$0.04 (+3.03%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ADCT with… →

ADCT Key Statistics

As of Sep 4, 2026
Trading
Open
$1.30
Previous Close
$1.32
Day's Range
1.30–1.37
52-Week Range
0.78–4.98
Volume
1.48M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.85
Valuation
Market Cap
$173.63M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.18
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.60
Financials (FY)
Revenue (FY)
$81.36M+14.85%
Net Income (FY)
−$142.62M
Profit marginThe share of revenue left as profit after all costs and taxes.
−121.77%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
127.67M
1-Year Return
−60.00%
Dividend and dates
Earnings Date
November 10, 2026
Avg Volume
1.79M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ADCT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−61.47%
2025+77.39%
2024+19.88%
2023−56.77%
2022−80.99%
2021−36.89%
2020 (partial year)+6.70%

As of September 4, 2026.

ADCT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$81.36M−$142.62M−175.3%
2024$70.84M−$157.85M−222.8%
2023$69.56M−$240.05M−345.1%
2022$209.91M−$157.13M−74.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$81.36M$75.56M−$107.21M−$142.62M−175.3%
2024$70.84M$64.89M−$129.59M−$157.85M−222.8%
2023$69.56M$67.03M−$165.05M−$240.05M−345.1%
2022$209.91M$206.61M−$122.99M−$157.13M−74.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ADCT Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricADCTDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio2.182.305% below
Profit margin−121.77%−3.14%118.6 pts below

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

ADC Therapeutics SA (ADCT) carries a market capitalisation of $173.63M. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. The company reports 188 employees.

Over the past 52 weeks the price has ranged from $0.78 to $4.98. ADCT last closed at $1.36 on September 4, 2026. That is +$0.04 (+3.03%) against the previous close. The latest close sits 74.36% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $81.36M. That is +14.85% against the prior fiscal year, when revenue was $70.84M. The same year closed with a net loss of $142.62M. Profit margin runs at −121.77%. That is 118.6 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Earnings per share on a trailing basis come to −0.6.

Across the 4 fiscal years on file, revenue moves from $209.91M in 2022 to $81.36M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 2.18. On price-to-sales that is 4.99% below the Drug Manufacturers - Specialty & Generic median of 2.3. 103 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.85. Daily returns over the trailing 6 years annualize to a volatility of 95.97%. Over the trailing twelve months the price has returned −60.00%. Across 5 years the annualized return works out at −45.37%.

Growth & Income

No dividend is on file for ADCT.

The strongest complete calendar year on file is 2025 at +77.39%; the weakest is 2022 at −80.99%. Of the 5 complete calendar years on file, 2 finished higher. 2026 is still running; the price is −61.47% year to date.

Peer Comparison

ADC Therapeutics SA (ADCT) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
ADC Therapeutics SA ADCT $173.63M —
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. ADC Therapeutics SA has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About ADC Therapeutics SA

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Visit website →